No-Fee CE: Myopia Beyond 2025

This course is designed to help readers understand the development of the disease of myopia. The article identifies areas in which clinicians can intervene to slow progression using the latest research evidence from the past year.

By
CARA FRASCO LAI, OD, MS
Nicky Lai, OD, MS
March 1, 2026
29 min

Contact Lens Spectrum

Objective:

To provide eyecare professionals with updated insights and evidence-based strategies for myopia management specifically as of 2026.

Approach:

Key Findings:

FDA approved a spectacle lens for myopia control in late 2025.
Parental myopia and reduced outdoor time are significant risk factors for developing myopia.
Low hyperopic reserve is the strongest predictor of myopic progression.
A delay in myopia onset can significantly reduce final myopia levels.
Emerging research indicates early changes in choroidal thickness may signal treatment efficacy.

Interpretation:

Understanding the onset factors of myopia can help mitigate its global effects, while effective management strategies can slow progression in children.

Limitations:

The study primarily focuses on East Asian populations, which may not generalize to other ethnic groups, potentially limiting the applicability of findings.
The mechanisms of myopia progression and treatment efficacy remain under investigation.

Conclusion:

Myopia management is evolving, with new tools and strategies emerging to address the increasing prevalence of the condition, highlighting the need for immediate action.